9,000 Shares in Moderna, Inc. (NASDAQ:MRNA) Purchased by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, Holdings Channel reports. The fund purchased 9,000 shares of the company’s stock, valued at approximately $374,000.

Several other institutional investors and hedge funds have also modified their holdings of MRNA. Wilmington Savings Fund Society FSB raised its position in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after acquiring an additional 587 shares during the last quarter. Compass Planning Associates Inc bought a new position in shares of Moderna during the 4th quarter worth approximately $37,000. Venturi Wealth Management LLC lifted its position in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after buying an additional 664 shares in the last quarter. Crowley Wealth Management Inc. acquired a new stake in shares of Moderna in the 4th quarter valued at approximately $41,000. Finally, MassMutual Private Wealth & Trust FSB raised its position in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after acquiring an additional 389 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Down 2.4 %

Shares of NASDAQ:MRNA opened at $25.11 on Monday. Moderna, Inc. has a 52 week low of $23.76 and a 52 week high of $170.47. The company’s fifty day moving average is $33.55 and its 200 day moving average is $42.61. The stock has a market cap of $9.71 billion, a PE ratio of -2.71 and a beta of 2.23.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on MRNA shares. The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and cut their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Evercore ISI set a $50.00 target price on shares of Moderna in a report on Friday, February 14th. Bank of America lowered their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a report on Tuesday, February 11th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $40.00 target price on shares of Moderna in a research report on Tuesday, February 18th. Finally, Leerink Partners dropped their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $59.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.